Breakout Ventures is the famous VC, which was founded in 2016. The leading representative office of defined VC is situated in the San Francisco. The fund was located in North America if to be more exact in United States.
The typical case for the fund is to invest in rounds with 6 participants. Despite the Breakout Ventures, startups are often financed by Dolby Family Ventures, Lux Capital, Data Collective DCVC. The meaningful sponsors for the fund in investment in the same round are Dolby Family Ventures, Blackhorn Ventures, Western Technology Investment. In the next rounds fund is usually obtained by Dolby Family Ventures, Western Technology Investment, Vulcan Capital.
The common things for fund are deals in the range of 10 - 50 millions dollars. The typical startup value when the investment from Breakout Ventures is 10-50 millions dollars. The fund is generally included in 2-6 deals every year. Comparing to the other companies, this Breakout Ventures performs on 18 percentage points less the average number of lead investments. Speaking about the real fund results, this VC is 9 percentage points less often commits exit comparing to other organizations. The important activity for fund was in 2019. The increased amount of exits for fund were in 2019.
The fund has no exact preference in a number of founders of portfolio startups. If startup sums 1 or 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Modern Meadow, Phylagen, Checkerspot Among the most successful fund investment fields, there are Pharmaceutical, Health Diagnostics.
We also calculated 3 valuable employees in our database.
Related Funds
Funds with similar focus
Fund Name | Location |
Gen-Probe | California, San Diego, United States |
Generac Power Systems | United States, Waukesha, Wisconsin |
GUS Holdings | - |
HEROZ | Japan, Tokyo |
Infield Capital | Boulder, Colorado, United States |
Jinsanban Touzi | China, Huangpu, Shanghai |
Josep Carreras Leukaemia Research Institute | Badalona, Catalonia, Spain |
Quadient | Bagneux, France, Ile-de-France |
Raymonds Capital, LLC | - |
Shanghai Dingmo Touzi Guanli Zhongxin (Limited Partnership) | - |
Sovereign Brands | - |
Tequity | - |
The Topol Group | - |
Triodos Investment Management | The Netherlands, Utrecht, Zeist |
Tsukuba Institute of Research | Ibaraki, Japan, Osaka Prefecture |
Vaultier7 | England, London, United Kingdom |
W&H Dentalwerk | Austria, Bürmoos, Salzburg |
Yadea | China, Jiangsu, Wuxi Shi |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
Passkey | 22 Oct 2024 | Cambridge, Massachusetts, United States | |||
TFC Therapeutics | 17 Aug 2023 | Nyack, New York, United States | |||
A-Alpha Bio | $22M | 25 Jul 2023 | Seattle, Washington, United States | ||
Parallel Bio | $4M | 20 Dec 2022 | Los Angeles, California, United States | ||
EnPlusOne Biosciences | $12M | 30 Sep 2022 | Watertown, Massachusetts, United States | ||
Canaery | $4M | 01 Jul 2022 | - | ||
Opus 12 | $130M | 29 Jun 2022 | Berkeley, California, United States | ||
Surf Bio | $16M | 12 Apr 2022 | Palo Alto, California, United States | ||
Phantom Neuro | $3M | 25 Mar 2022 | Austin, Texas, United States |
– Carbon transformation startup Twelve has raised $57 million in Series A funding.
– The round was led by Capricorn Technology Impact Fund and Carbon Direct Capital Management.
– Seed round lead DCVC, as well as Munich Re Ventures, Microsoft Climate Innovation Fund, Breakout Ventures, and Evok Innovations also participated in the round.
– Twelve is pioneering a new market category called carbon transformation with its proprietary catalyst technology that transforms CO2 into critical chemicals, materials and fuels that are conventionally made from fossil fuels.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
Passkey | 22 Oct 2024 | Cambridge, Massachusetts, United States | |||
TFC Therapeutics | 17 Aug 2023 | Nyack, New York, United States | |||
A-Alpha Bio | $22M | 25 Jul 2023 | Seattle, Washington, United States | ||
Parallel Bio | $4M | 20 Dec 2022 | Los Angeles, California, United States | ||
EnPlusOne Biosciences | $12M | 30 Sep 2022 | Watertown, Massachusetts, United States | ||
Canaery | $4M | 01 Jul 2022 | - | ||
Opus 12 | $130M | 29 Jun 2022 | Berkeley, California, United States | ||
Surf Bio | $16M | 12 Apr 2022 | Palo Alto, California, United States | ||
Phantom Neuro | $3M | 25 Mar 2022 | Austin, Texas, United States |